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with the use of endovascular repair to treat thoracic
aortic diseases
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Matthew L. Stone, MD,a Gilbert R. Upchurch Jr, MD,b and Gorav Ailawadi, MD,c Charlottesville, Va
Objective: Descending thoracic aortic diseases may be treated with either open thoracic aortic repair or thoracic endo-
vascular aortic repair (TEVAR). Previous studies have demonstrated that race and socioeconomic status (SES) affect
access to care and treatment allocation in vascular surgery. We hypothesized that racial minorities and lower SES patients
have decreased propensity to have their thoracic aortic disease treated with TEVAR.
Methods: Weighted discharge records for patients who underwent either open thoracic aortic repair or TEVAR between
2005 and 2008 were evaluated using the Nationwide Inpatient Sample. Patient records were stratiﬁed by therapeutic
intervention (open repair vs TEVAR). Differences in baseline comorbidities, race, and SES were compared. To account
for the effects of comorbidities and other factors, hierarchical logistic regression modeling was used to determine the
likelihood for TEVAR performance based on differences in patients’ race and SES.
Results: A total of 60,784 thoracic repairs were analyzed, the majority (79.4%) of which were open repairs. The most
common race was white (78.2%), followed by black (9.1%), Hispanic (5.7%), Asian or Paciﬁc Islander (2.9%), and Native
American (0.7%). Patients were divided into quartiles according to SES with 20.6% of patients in the lowest SES quartile,
24.3% in the second quartile, 26.4% in the third quartile, and 28.8% in the highest SES quartile. Indications for treatment
were similar for both treatment groups. After adjusting for multiple patient and hospital factors, race and SES were
signiﬁcantly associated with treatment modality for thoracic aortic disease. Black, Hispanic, and Native American pop-
ulations had increased adjusted odds ratios of TEVAR performance compared with white patients. Similarly, lower SES
correlated with increased use of TEVAR.
Conclusions: Contrary to our initial hypothesis, racial minorities (Black, Hispanic, and Native American) and patients with
lower median household incomes have a greater association with the performance for TEVAR after accounting for patient
comorbid disease, indication for treatment, payer status, and hospital volume. These results indicate that traditional racial
disparities do not persist in TEVAR allocation. (J Vasc Surg 2013;58:1476-82.)Thoracic endovascular aortic repair (TEVAR) has rapidly
gained popularity for the treatment of thoracic aortic disease.
TEVAR has been associated with improved outcomes
compared with open surgical aortic repair, although long-
term outcomes remain unknown.1-3 Compared with patients
treated with open aortic reconstruction, patients undergoing
TEVAR have decreased operative mortality, paralysis, renal
insufﬁciency, cardiac and pulmonary complications, and
lengthof stay.3,4The spectrumof aorticpathologies amenable
to either open repair or TEVAR has evolved and includes
thoracic aortic aneurysms, thoracic dissection, intramural
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6Throughout health care, disparities have existed bet-
ween patients of different racial backgrounds, with racial
minority patients often receiving substandard care leading
to worse outcomes following treatment.5 Similar racial
disparities have been demonstrated in multiple past evalua-
tions of common vascular operations.6-9 Access to care and
allocation of advanced medical technology, including endo-
vascular techniques, vary according to race and socioeco-
nomic status (SES).10-12 Racial minorities are less likely to
have a regular medical provider and often receive inferior
quality of care with worse access to specialists and advanced
technology than white patients.11,13,14 In regard to abdom-
inal aortic aneurysms, racial minorities are almost one-half as
likely to receive endovascular treatment as opposed to open
repair.15 Many racial disparities are related to underlying
differences in SES, demonstrated by a reduction in the
disparities when the effects of socioeconomic factors are
controlled.10,12 In organ transplantation and oncology,
prior study has shown that SES independently inﬂuences
treatment allocation.16,17 Therefore, although race and
SES are related, both race and SES are likely to be indepen-
dently involved in health care inequalities.
While mortality following TEVAR does not appear
affected by race,18 the question of allocation of TEVAR
to racial minorities and patients from lower SES remains
undeﬁned and may differ. Based on established health
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that similar disparities would exist regarding the alloca-
tion of TEVAR, with racial minorities and patients from
lower SES being less likely to receive TEVAR. Accord-
ingly, the purpose of this study was to examine the rela-
tionship of race and SES on resource allocation with
TEVAR for thoracic aortic surgery. Importantly, TEVAR
may provide a more recent example of health care dispar-
ities in vascular surgery since TEVAR has only been adop-
ted into the treatment paradigm for thoracic aortic
disease since 2005.
METHODS
Data source. Patient data were obtained from the
Nationwide Inpatient Sample (NIS) from 2005 to 2008.
The NIS is the largest publicly available all-payer inpatient
care database in theUnited States. It is based off of discharge
data from over 1000 hospitals and represents a 20% random
sample of nonfederal hospitals of the United States,
including both academic and private centers. Importantly,
the NIS contains unique hospital and county identiﬁers that
can be linked to area resource ﬁles for an estimation of
community-level income status.
The University of Virginia Institutional Review Board
exempted the study from formal review because of the
absence of unique patient identiﬁers and the collection of
data for purposes other than research.
Patients. Patients who were treated for thoracic aortic
disease were identiﬁed with International Classiﬁcation of
Disease, 9th revision, Clinical Modiﬁcation coding system
for procedure codes for open thoracic aortic repair (38.35
or 38.45) or TEVAR (39.73 or 39.79) from the NIS
between 2005 and 2008. The burden of baseline comorbid
disease was evaluated using Elixhauser comorbid disease
categories, which comprise 30 comorbid measures that are
associated with increased patient length of stay, hospital
charges, and mortality.19 The Elixhauser measures were
chosen over alternative comorbid indices (ie, the Charlson-
Deyo index), as the Elixhauser method has been proven
superior for use with large administrative databases, such as
the NIS.20,21 Patients were stratiﬁed based on race into the
following categories: white, black, Hispanic, Asian or Paciﬁc
Islander, Native American, and other. Individual SES was
proxied using median household income-based Zone
Improvement Plan code as provided by the NIS and cate-
gorized into quartiles: (1) less than $25,000, (2) $25,001-
$30,000, (3) $30,001-$35,000, and (4) greater than
$35,000.22 Additionally, payer status, procedure year,
elective status, and hospital procedure volume were
considered. Hospital procedure volume for both open
repair andTEVARwas divided intoquartiles for comparison:
low (<11), medium (11-36), high (37-92), and very
high (>92).
Statistical analysis. Statistical analysis was aimed at
testing the null hypothesis that the method of thoracic
aortic repair was not signiﬁcantly different as a function
of race or SES. To accomplish this, patients were divided
into two groups based on therapeutic intervention: openthoracic aortic repair or TEVAR. Discrete patient charac-
teristics were compared by univariate testing with Pearson
c2 or Fisher exact test where appropriate. Continuous
data, including patient age, hospital length of stay, and
total charges were compared using single-factor analysis
of variance or the Mann-Whitney U test for non-normal
distributions.
To evaluate the relationship of race and SES on the
allocation of TEVAR for thoracic aortic disease, hierar-
chical multivariable logistic regression modeling was
used. Patient variables were determined a priori based
upon clinical effect or confounding status of the perfor-
mance of TEVAR. The model accounted for difference
in patient characteristics, including age, sex, Elixhauser
comorbidities, payer status, and indication for thoracic
aortic repair. Additionally, the effects of procedure year
and hospital volume were considered, including total
volume for both open repair and TEVAR, individual
volume for open repair, and individual volume of TEVAR.
Using hierarchical logistic regression, the ability of race or
SES to predict TEVAR performance could be determined,
controlling for both the inﬂuences of other independent
variables on TEVAR usage, as well as the inﬂuence of
race or SES on other independent variables. Clustering
of cases and diagnoses were addressed at the hospital level
and the level of individual diagnoses present on admission.
The random effects of individual hospitals were controlled
within the model using the American Hospital Associa-
tion Identiﬁcation number. Wald c2 test was used to
determine the relative strength of association between
model variables and the performance of TEVAR. The
ability of the model to account for the performance of
TEVAR was evaluated using the area under the receiver
operating characteristic curve (area under the curve),
with 1.0 indicating perfect discrimination and 0.5 indi-
cating that the model has equal chance of predicting the
desired outcome.
To address the issue of collinearity between race and
SES within the statistical model, each factor’s regression
coefﬁcient, t-test statistic, standard error, and coefﬁcient
P value were examined. With positive regression coefﬁ-
cients, small and narrow standard errors, and signiﬁcant
t-test statistics, race and SES could be evaluated indepen-
dently of one another. Further evaluation of collinearity
was achieved by performing additional analyses without
the inclusion of race and SES as covariates. Persistence of
statistical signiﬁcance and minimal attenuation of the
observed effect validated the study and limited the possible
effects of race and SES correlation.
Normally distributed continuous variables are presented
as mean6 standard deviation, whereas non-normally distrib-
uted data are presented as median (interquartile range). The
associations between the performance of TEVAR and race
or SES are presented as adjusted odds ratios with 95% conﬁ-
dence intervals. Statistical signiﬁcance was deﬁned as a P value
of less than .05. All analyses were performed using PASW
Statistics software, v. 20.0 with the complex sample module
(IBM Cooperation, Chicago, Ill).
Table I. Patient demographics with univariate comparisons of patients receiving open TA repair or TEVAR
Open TA repair TEVAR
Signiﬁcance (P value)No. of patients % No. of patients %
Total patients 48,233 79.4 12,551 20.6 <.001
Patient characteristics
Mean age 6 SD, years 57.0 6 20.0 65.3 6 16.7 <.001
Male sex 31,669 65.7 7748 61.8 <.001
Elective cases 25,995 53.9 6769 54.1 .697
Select Elixhauser comorbid disease categories
Hypertension 26,916 55.8 8510 67.8 <.001
Peripheral vascular disease 17,749 36.8 4029 32.1 <.001
Chronic pulmonary disease 8730 18.1 3615 28.8 <.001
Deﬁciency anemia 5450 11.3 1280 10.2 .13
Diabetes 4669 9.7 1717 13.7 <.001
Renal failure 3424 7.1 1819 14.5 <.001
Obesity 3213 6.7 749 6 .005
Rheumatoid arthritis/collagen vascular disease 766 1.6 274 2.2 <.001
Congestive heart failure 775 1.6 148 1.2 <.001
Liver disease 418 0.9 118 0.9 .432
Etiology
Intact TAA 22,437 46.5 5603 44.6 <.001
Ruptured TAA 1130 2.3 663 5.3 <.001
Intact TAAA 2455 5.1 1700 13.5 <.001
Ruptured TAAA 446 0.9 158 1.3 .001
TA dissection 12,448 25.8 2929 23.3 <.001
Other TA pathology 174 0.4 0 0 <.001
Payer status <.001
Private insurance 21,454 44.5 3635 29
Medicare 19,529 40.5 7242 57.8
Medicaid 3912 8.1 814 6.5
Self-pay 1615 3.4 500 4
Uninsured 157 0.3 30 0.2
Other 1512 3.1 315 2.5
Race <.001
White 28,468 79.4 6915 73.7
Black 2934 8.2 1174 12.5
Hispanic 1964 5.5 590 6.3
Asian or Paciﬁc Islander 999 2.8 311 3.3
Native American 200 0.6 134 1.4
Other 1281 3.6 260 2.8
Median household income <.001
<$25,000 9305 19.8 2891 23.8
$25,001-$30,000 11,100 23.8 3290 27.0
$30,001-$35,000 12,497 26.5 3131 25.7
>$35,001 14,179 30.1 2852 23.4
SD, Standard deviation; TA, thoracic aortic; TAA, thoracic aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm; TEVAR, thoracic endovascular
aortic repair.
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TEVAR patients have more comorbidities. Between
2005 and 2008, 12,312 unweighted cases were identiﬁed
representing 60,784 patients who underwent thoracic
aortic repair. The majority of patients were treated with
open repair (79.4%), and the remainder was treated with
TEVAR. Differences in treatment groups are shown in
Table I. Patients receiving TEVAR were more likely to
be older, female, and have more comorbidities, including
hypertension, diabetes, chronic pulmonary disease, and
renal failure. Additionally, patients treated with TEVAR
were more likely to have Medicare insurance, whereas the
most common payer status for open repair was private
insurance. Overall, the most common indications for eithertreatment modality were intact thoracic aortic aneurysms
(46.1%) and thoracic aortic dissection (25.3%). Ruptured
thoracic or thoracoabdominal aortic aneurysms accounted
for <4% of the overall cases but were slightly more
common in the group treated with TEVAR. The indica-
tions for TEVAR and open repair were similar, although
small differences in diagnoses were statistically signiﬁcant
because of the large sample size. Elective cases accounted
for 54% of both TEVAR and open repairs and did not differ
signiﬁcantly between the groups (P ¼ .697).
The distribution of patient race by procedure is illus-
trated in Fig 1. Univariate analyses demonstrated signiﬁ-
cant differences in race and SES between patients
receiving open repair and TEVAR with 26.3% of TEVAR
Table II. Ratios of TA aneurysms to TA dissection as the
indications for TA repair according to race and SES
TA aneurysm:
TA dissection
Signiﬁcance
(P value)
Race <.001
Hispanic 4.56
Asian or Paciﬁc Islander 3.57
White 3.44
Other 3.00
Black 2.51
Native American 2.38
Median household
income
<.001
<$25,000 3.35
$25,001-$30,000 3.31
$30,001-$35,000 3.12
>$35,001 3.37
SES, Socioeconomic status; TA, thoracic aortic.
Fig 1. Racial distribution of patients according to treatment for thoracic aortic disease. TA, Thoracic aortic; TEVAR,
thoracic endovascular aortic repair.
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repair patients (P < .001). In regard to the proportion of
patients receiving TEVAR according to race, 28.6% of
black patients received TEVAR, whereas only 19.5% of
white patients were treated with TEVAR (P < .001).
Regarding SES, the total cohort was divided into quartiles
with 20.6% in the lowest SES, 24.3% in the second SES
group, 26.4% in the third SES group, and 28.7% of patients
in the highest SES group. More patients in the lowest-
income quartile received TEVAR compared with patients
in the highest income quartile (23.7% lowest SES vs
16.7% highest SES; P < .001).
For all races and SES quartiles, thoracic aortic aneu-
rysms were more common than aortic dissections. In
comparing difference races, Hispanic patients were signiﬁ-
cantly more likely to have thoracic aortic aneurysms as
the indication for thoracic aortic repair compared with
other groups, whereas black patients and Native Americans
had a lower ratio of aneurysms to dissections (Table II).
The ratio of thoracic aortic aneurysms to dissections was
similar among all SES groups with thoracic aortic aneu-
rysms being three times as common as thoracic aortic
dissections.
TEVAR has increasing popularity and lower
resource utilization. Although the volume of open repairs
for thoracic aortic disease remained relatively stable from
2005 to 2008, the number of TEVARs performed increased
drastically following Food andDrug Administration approval
in 2005. The majority of patients undergoing either open
repair or TEVAR were treated at very high-volume hospitals
(77% open repair and 80% TEVAR; P< .001). The distribu-
tion of races did not vary signiﬁcantly by hospital volume for
either open repair or TEVAR (Fig 2). Importantly, lower
overall thoracic aortic repair volume hospitals did not treat
a higher proportion of racial minority patients.
The study cohort fromNIS demonstrated similar trends
to other published literature in terms of decreased resource
utilization with TEVAR.2,23 The performance of TEVAR
was associated with a shorter length of stay by over 2 days,
and total charges were signiﬁcantly less when TEVAR was
performed compared with open repair (Table III). Unad-
justed in-hospital mortality following open repair was highercompared with patients treated with TEVAR (9.8% open
repair vs 6.9% TEVAR; P < .001).
Minorities and lower SES associated with
TEVAR. Accounting for multiple patient comorbidities
and hospital factors, multivariate logistic regression analysis
demonstrated that race and SESwere signiﬁcantly associated
treatment allocation for thoracic aortic disease.Racialminor-
ities and patients with lower incomes were independently
associated with an increased propensity to receive endovas-
cular treatment for thoracic aortic disease (Table IV).
Compared with white patients, black and Hispanic patients
were 71% and 70% more likely to receive TEVAR, respec-
tively. Native Americans, although representing a small
portion of patients, were more than twice as likely to receive
TEVAR compared with patients of white race. TEVAR was
also more likely to be performed in patients with lower
incomes, with the odds of TEVAR in patients in the lowest-
income quartile being 24% more than the highest-income
quartile. In comparison with the highest-income group, all
lower-income quartiles were independently associated with
increased likelihood to be treated with TEVAR with the
propensity of receiving TEVAR increasing in a proportional
manner to decreasing income status.
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Fig 2. Distribution of patient race according to hospital procedure volume. NS, Nonsigniﬁcant; TEVAR, thoracic
endovascular aortic repair.
Table III. Procedure-related differences between open repair and TEVAR with univariate comparisons
Open TA repair TEVAR
Signiﬁcance (P value)Median IQR Median IQR
Total length of stay, days 8 6-15 6 3-12 <.001
Total charges $121,345 $82,125-$201,052 $111,191 $73,991-$190,707 <.001
No. of patients % No. of patients %
Mortality 4725 9.8 866 6.9 <.001
Hospital volume quartile <.001
Low (<11) 837 1.8 196 1.6
Medium (11-36) 2914 6.2 529 4.1
High (37-92) 7324 15.5 1749 14.1
Very high (>92) 37,157 76.5 10,007 80.2
Calendar year <.001
2005 11,983 24.8 671 5.3
2006 11,689 24.2 3839 30.6
2007 10,792 22.4 3257 26
2008 13,768 28.5 4783 38.1
IQR, Interquartile range; TA, thoracic aortic; TEVAR, thoracic endovascular aortic repair.
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Racial disparities seen in other aspects of general and
vascular surgery do not appear to persist in the allocation
of TEVAR for the treatment of thoracic aortic diseases.
White patients and patients within the highest SES did not
have a greater association with TEVAR usage. In contrast
to our hypothesis, racial minorities and patients from lower
SES have a greater association with TEVAR performance
compared with white and highest SES patients. Although
race and SES signiﬁcantly overlap, the present study impor-
tantly demonstrates that race and SES each independently
correlate with the use of TEVAR.
Goodneyet al recently evaluated the relationship between
race andmortality following descending thoracic aortic repair
in over 12,500 Medicare patients.18 In their cohort of
patients, 29% of nonwhite patients with intact thoracic aortic
aneurysms were treated with TEVAR, whereas only 17% ofwhite patientswere treatedwithTEVAR.Although theirﬁnd-
ings are limited to intact thoracic aortic aneurysms in the
Medicare population and do not account for the inﬂuence
of multiple patient and hospital variables, the increased rate
of TEVAR in nonwhite patients is similar to the ﬁndings of
the present study and supports correlation between racial
minorities and increased use of TEVARs.
These ﬁndings regarding treatment allocation for
thoracic aortic disease counter the racial and socioeconomic
inequalities that have been described in the quality of patient
care and the allocation of endovascular repair for abdominal
aortic aneurysms.14,15 TEVAR has similarly deﬁed other
established health care relationships, such as the relationship
between procedure volume and outcome and between race
and mortality. Outcomes following TEVAR do not appear
to differ according to hospital volume strata, illustrated by
low-volume centers having similar outcomes to high-volume
Table IV. Logistic regression analysis for the
performance of TEVAR based on race and SES
Factor
Adjusted odds ratio
for TEVAR
95% Conﬁdence
interval
Race
Native American 2.37 1.44-3.91
Black 1.71 1.37-2.13
Hispanic 1.70 1.22-2.37
Asian or Paciﬁc Islander 1.34 0.90-1.99 (NS)
Other 0.98 0.65-1.49 (NS)
White (reference) 1.00
SES (mean income quartile)
1. (<$25,000) 1.24 1.03-1.62
2. ($25,001-$30,000) 1.17 1.03-1.38
3. ($30,001-$35,000) 1.13 1.02-1.32
4. (>$35,000, reference) 1.00
AUC, Area under the curve; NS, nonsigniﬁcant; SES, socioeconomic status;
TEVAR, thoracic endovascular aortic repair.
Models adjusted for multiple patient demographics, procedure year, and
hospital characteristics, including hospital volumes for TEVAR and open
repair.
Model performance: AUC ¼ 0.751; Nagelkerke pseudo R2 ¼ 0.195.
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minorities have increased mortality rates following complex
surgery,25 mortality following TEVAR is not signiﬁcantly
affected by race.18
The decision to treat a patient with TEVAR is inﬂuenced
bymultiple patient and hospital variables. Although race and
SES are related toTEVARallocation, aneurysmmorphology
is the most important factor in the treatment paradigm. In
patients with suitable anatomy, TEVAR is rapidly gaining
acceptance as the ﬁrst-line therapy. Differences in disease
severity may explain some of the increased association of
TEVAR with racial minorities and lower SES patients. Black
and lowSES patients have been shown to delay presentations
for medical care.26 Consequently, racial minorities and
patients with low SES often present with more severe symp-
toms requiring emergent repair.27 In the present study,
patients receiving TEVARweremore likely to have ruptured
thoracic aortic aneurysms (5.3% vs 2.3% with open repair;
P < .001). Although differences in treatment indication
were controlled by the statistical propensitymodel, variances
in thoracic aortic disease pathology and speciﬁc anatomic
features, such as involvement of the left subclavian artery
origin and diameters of iliac or femoral vessels, are not
captured in large administrative databases and may differ
between patients. These individual differences may play
a role in the treatment selection and may partially explain
the increased performance of TEVAR.
Other factors inﬂuencing treatment decisions include
patient comorbidities, age, hospital volume, and payer
status. Racial minorities and patients from lower SES are
more likely to be treated at hospitals with lower volume
for complex surgery.28,29 Surgeons at low-volume centers
are frequently performing TEVAR, as it avoids the complex
challenges of open repair. However, the addition of both
hospital volumes for TEVAR and for open repair in the
multivariate analysis did not signiﬁcantly alter the adjustedodds ratios for TEVAR performance based on race or SES.
Therefore, the current results cannot be explained by
hospital volume alone. Regarding payer status, patients
who were treated with TEVAR were more likely to have
Medicare, whereas patients treated with open repair were
more likely to have private insurance. Medicare patients
are typically older than 65 years of age or have end-stage
renal disease, thereby increasing their comorbidities. As
a result, more Medicare patients may not have been appro-
priate candidates for open repair and were therefore treated
with TEVAR.
Controlling for common patient and hospital character-
istics, including payer status, does not fully explain the
increased association between TEVAR performance and
racial minorities and lower economic classes. The correlation
between increased TEVAR performance in racial minorities
and lower SES patients is unlikely to be a direct causal rela-
tionship. Rather, race and SES are likely surrogate factors
representing multiple patent-speciﬁc variables that result in
increased likelihood for TEVAR performance. The speciﬁc
patient factorsmay include patient beliefs, level of education,
access to care, and differences in the nature of the thoracic
aortic disease. For example, black patients have been shown
to be less likely to choosemajor surgical treatment compared
with white patients.30,31 Additionally, physician distrust
varies signiﬁcantly based on race and SES with racial minor-
ities and lower SES associatedwith higher levels of distrust.32
To more fully evaluate the multifactorial explanation of
TEVAR allocation, surgeon and patient surveys would be
required to gauge individual bias and beliefs.
As with all retrospective reviews of national databases, the
present study has limitations. First, the NIS is based off of
administrative data collected for reimbursement purposes,
which allows gaps in clinical information and is subject to
errors.33 With large databases, the appropriateness of treat-
ment cannot be assessed, and patients who were not suitable
for repair are not captured in the study cohort. Second, our
study was limited from 2005 to 2008. Since TEVAR was
Food and Drug Administration-approved in 2005, it has
been rapidly adopted.With increasing prevalence of TEVAR,
it is expected that racial minorities and lower socioeconomic
classes are even more likely to be treated with TEVAR
compared with open repair. Third, the NIS captures only
20%of hospital discharges. Although this is presumably repre-
sentative of the population at large, sampling error may affect
ﬁndings. Fourth, median household income based on patient
Zone ImprovementPlan code is an approximationof SES and
lacks speciﬁcity and range.30 Regardless of method, SES is
challenging to accurately represent because it is dynamic
over time, difﬁcult to collect individual economic data, and
does not account for retired persons.34 Last, race and SES
are related. Although we believe the relationship between
TEVAR and both race and SES are independent, collinearity
between race and SES may partly explain the increased odds
ratios in racial minorities and lower SES patients.
In conclusion, racial disparities seen in other aspects of
surgery do not persist in the resource allocation of TEVAR.
TEVAR is unique in that it is an example of advanced
JOURNAL OF VASCULAR SURGERY
1482 Johnston et al December 2013medical technology that has a greater association with racial
minorities and lower socioeconomic classes. The increased
correlation between TEVAR and racial minorities and
patients from lower SES is multifactorial and cannot be
fully explained by common patient or hospital factors.
Trends in TEVAR allocation indicate that treatment
disparities based on race and SES are decreasing in vascular
surgery.
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